<DOC>
	<DOCNO>NCT00745316</DOCNO>
	<brief_summary>The main purpose study determine safety tolerability tonapofylline ( BG9928 ) give different dos patient heart failure renal insufficiency . This study also explore : - Disease related quality-of-life - Exercise capacity - Renal function - Concomitant medication</brief_summary>
	<brief_title>Oral Tonapofylline ( BG9928 ) Patients With Heart Failure Renal Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Adenosine A1 Receptor Antagonists</mesh_term>
	<criteria>18 year age old Diagnosis heart failure require hospitalization &gt; 1 ≤12 month prior screen NYHA Class III IV time screen Renal insufficiency define eGFR ≥20 ≤70 mL/min/1.73 m2 Negative pregnancy test History allergic reaction xanthinecontaining compound . History seizure History stroke Serious systemic infection Sustained systolic blood pressure &gt; 170 &lt; 90 mmHg Myocardial infarction within 30 day Day 1 Hemodynamically destabilize arrhythmia within 30 day Day 1 Uncorrected hemodynamically significant primary valvular disease Known obstructive restrictive cardiomyopathy Cardiac surgery within 60 day prior Day 1 Likely undergo cardiac transplantation , device implantation , cardiac surgery within next three month Evidence malignancy within 6 month prior Day 1 . Participation investigational study drug device within 30 day prior Day 1 . Receiving aminophylline , theophylline , pentoxifylline , dyphylline adenosine Presence clinically significant condition might interfere optimal safe participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Congestive Heart Failure</keyword>
</DOC>